RVNC Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 107890 min ago

@ $5.59

Wydano: 14 vas. 2024 @ 20:54

Zwrot: -33.48%

Poprzedni sygnał: vas. 14 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: 3.36 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 20:04):

Stats
Dzisiejszy wolumen	2.01M
Średni wolumen	1.84M
Kapitalizacja rynkowa	387.68M
EPS	$0 ( 2024-02-28 )
Następna data zysków	( $-0.660 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.970
ATR14	$0.0100 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Jordan Erica	Sell	2 392	Common Stock
2024-03-15	Sjuts Dustin S	Sell	2 967	Common Stock
2024-03-18	Sjuts Dustin S	Sell	9 211	Common Stock
2024-03-15	Moxie Dwight	Sell	3 269	Common Stock
2024-03-18	Moxie Dwight	Sell	8 125	Common Stock

INSIDER POWER
64.41
Last 97 transactions
Buy: 2 720 068 \| Sell: 629 333

Wolumen Korelacja

Długi: -0.05 (neutral)

Krótki: 0.84 (strong)

Signal:(58.58) Same movement expected

Revance Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
SYKE	0.944
SPRB	0.923
BRACU	0.922
XLRN	0.921
PIRS	0.918
ATCX	0.918
MESA	0.915
VRME	0.915
JFIN	0.913
OVID	0.907

10 Najbardziej negatywne korelacje
AHPI	-0.934
TUEM	-0.902
VERA	-0.881
ARDS	-0.865
CYTO	-0.86
NAKD	-0.852
LCAP	-0.85
CFV	-0.844
JRJC	-0.843
APM	-0.837

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Revance Therapeutics Inc Korelacja - Waluta/Towar

-0.31
( neutral )

-0.49
( neutral )

0.00
( neutral )

0.33
( neutral )

0.37
( neutral )

Revance Therapeutics Inc Finanse

Annual	2023
Przychody:	$234.04M
Zysk brutto:	$145.98M (62.38 %)
EPS:	$-3.83

FY	2023
Przychody:	$234.04M
Zysk brutto:	$145.98M (62.38 %)
EPS:	$-3.83

FY	2022
Przychody:	$132.57M
Zysk brutto:	$80.90M (61.03 %)
EPS:	$-4.90

FY	2021
Przychody:	$77.80M
Zysk brutto:	$54.39M (69.91 %)
EPS:	$-4.17

Financial Reports:

No articles found.

Revance Therapeutics Inc

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.